Perrigo Completes Dermacosmetics Business Sale to Karo Healthcare

SEC 8-K Filing Notice

Company: Perrigo Company plc (PRGO) Filing Date: 2026-04-30 Accession Number: 0001585364-26-000040

Items Filed

Item 2.01: Completion of Acquisition or Disposition of Assets Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Summary

Perrigo Company plc (PRGO) announced the completion of the sale of its Dermacosmetics Business to Karo Healthcare, an affiliate of Karo Healthcare AB and an investment vehicle managed by an affiliate of KKR & Co., Inc. The transaction closed on April 30, 2026, with Perrigo receiving €305.6 million in cash, including working capital adjustments. Perrigo is also eligible for up to €27.0 million in contingent cash consideration based on the Dermacosmetics Business's performance over the next three years. This divestiture aligns with Perrigo's strategy to focus on its core consumer self-care businesses.

Key Takeaways

Perrigo completed the sale of its Dermacosmetics Business to Karo Healthcare for €305.6 million plus potential contingent consideration.
The Dermacosmetics Business includes Aco Hud Nordic AB and related cosmetic, medicinal product, and medical device assets in Northern Europe, the Netherlands, and Poland.
The sale agreement was initially announced on July 13, 2025.
Perrigo may receive up to €27.0 million in additional payments based on the future performance of the divested business.
The transaction is expected to allow Perrigo to focus on its core consumer self-care portfolio.

Analysis

This divestiture signals Perrigo's strategic shift towards a more focused portfolio. For investors, the immediate impact is the influx of cash, which Perrigo can use for debt reduction, strategic acquisitions, or share repurchases. The potential for contingent payments adds further upside. Competitors in the consumer self-care market may see this as an opportunity for Perrigo to become a more formidable player in that space. The broader pharmaceutical market will observe how Perrigo redeploys the capital and whether this strategic refocus leads to improved financial performance and growth.

This post was automatically generated from an SEC 8-K filing.